Latest Issue

Sustainability in Drug Delivery171

Issue No #171 April/May 2025 May 1st, 2025

Issue 171 - Apr/May 2025

Inside the magazine

Interview: A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

Dr Patrick Anquetil

Portal Instruments

Interview: A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

In this exclusive interview with ONdrugDelivery’s Guy Furness, Dr Patrick Anquetil offers insight into the extensive waste involved in the self-injection market. He explains how pivoting from a model focused on fully disposable devices to reusable electromechanical autoinjectors could offer a more sustainable and cost-effective path forward.

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin Van der Heul

ALBIS Distribution

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin van der Heul considers the increasing regulatory pressure on manufacturers to deliver sustainable solutions in the medical device industry. This article explores these innovations and their impact on the future of drug delivery devices.

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

PCI Pharma Services

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

Ann Cartwright and Tim Hansen explain the five key components of PCI's sustainable procurement strategy to increase efficiency, meet regulatory demands and support business resilience and sustainability in the long term.

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group examines how semi-reusable, modular designs like its Vertiva 10 mL on-body delivery system can reconcile patient demands for ease of use with growing expectations for sustainability, sharing new UK preference data and lifecycle analysis that reveal significant waste and emissions reductions.

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

Lorenzo Biasio and Gloria Skibba discuss the integration of Ypsomed’s Net Zero Program into its self-injection platforms. With the evolution of GLP-1 therapies and the exploration of higher-dose formulations, the demand for higher-volume autoinjectors is increasing; this article explains how Ypsomed has also applied its sustainability principles to larger-volume delivery.

Interview: The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

Interview: The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

Aptar Pharma’s Chris Baron discusses how the company has developed a new metering valve technology platform – ZEN30 Futurity™ – that is compatible with leading lower-GWP propellants. By collaborating with drug developers, regulators and the pMDI supply chain, Aptar Pharma aims to support the reduction of the CO₂ footprint of pMDIs while ensuring that the pharmaceutical industry’s strict regulatory requirements are met or exceeded.

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

Jack Eaton considers the current landscape for drug delivery and packaging, and how developments and research in nonwoven and fibrous materials can help businesses address the problem of per- and polyfluoroalkyl substances.

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

Sas Maheswaran discusses how artificial intelligence, data and strategic partnerships can make clinical trials more sustainable – both financially and environmentally.

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

Julian Lotz introduces bio-based solutions for drug delivery devices, excelling in quality while meeting upcoming sustainability regulations, and explores the future of bioplastics in the healthcare sector.

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

Luca Chiochia discusses the vital role of coloured plastics in medical devices and how the use of pre-coloured, pre-tested solutions can provide not only a significantly reduced regulatory burden for device developers and manufacturers but also a higher quality end product, going on to explain how the company is approaching the critical subject of producing more sustainable polymers.

Top